{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000026","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.727999+00:00","generated_at":"2026-05-23T05:50:29.566254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie Q1 adj EPS $2.46 (+6.5%), revenue $13.34B (+8.4%); raises FY EPS guidance to $12.09-$12.29","bullets":["Q1 GAAP EPS $0.72 (down 6.5%), adjusted EPS $2.46 (up 6.5%); revenue $13.34B (+8.4% reported).","Immunology growth: Skyrizi $3.43B (+70.5%), Rinvoq $1.72B (+57.2%); Humira $1.12B (-50.6%).","Aesthetics down 11.7% to $1.10B; Botox Cosmetic -12.3%, Juvederm -22.2%.","FY2025 adjusted diluted EPS guidance raised to $12.09-$12.29 from $11.99-$12.19.","CEO Robert A. Michael elected chairman effective July 1, 2025, succeeding Richard A. Gonzalez."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000026","json":"https://secwatch.observer/filing/0001551152-25-000026.json","markdown":"https://secwatch.observer/filing/0001551152-25-000026.md","text":"https://secwatch.observer/filing/0001551152-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/0001551152-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:50:29.566254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}